OncoMed Pharmaceuticals Logo

Email this page: News Release

OncoMed Presents Data From Brontictuzumab, Vantictumab and Anti-DLL4/VEGF Bispecific Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics


Separate multiple addresses with commas. Maximum 200 characters.

These email addresses will be used to email the page on your behalf and will not be used by OncoMed Pharmaceuticals for any marketing purposes.


This helps OncoMed Pharmaceuticals prevent automated submissions.